[ad_1]
This article is over a month old and may contain outdated advice from authorities regarding coronary heart disease.
Stay up-to-date on the NRK overview or on the FHI website.
During Easter (week 13), the National Institute of Public Health (NIPH) sent 78,198 doses of the Pfizer vaccine to municipalities. There was a decrease from the previous week, when 91,404 doses were shipped.
After the AstraZeneca vaccine was discontinued, it is mainly the Pfizer vaccine that is used in Norway.
Now chief physician Preben Aavitsland at FHI says there will be a sharp increase in the number of vaccinations in the coming weeks.
– In week 14, we shipped 150,960 doses of the Biontech-Pfizer vaccine to municipalities, Aavitsland writes in an email to NRK.
In practice, this means almost doubling the number of vaccines in a week.
Even more the following week
The following week, week 15, there will be even more doses of vaccine.
FHI then ships 150,930 doses of the Pfizer vaccine. Additionally, 27,800 doses of the vaccine come from Moderna.
In total, there will be 178,730 doses of vaccine in one week.
– Since then, we have not distributed yet, but we expect about the same level of the Biontech-Pfizer vaccine in the rest of April, says Aavitsland.
It states that Norway will also receive around 50,000 doses of Janssen during the month.
– We went from 360,000 doses in March to 590,000 doses in April, and that’s very positive, says Aavitsland.
New factory in Germany
Preben Aavitsland, chief physician at the National Institute of Public Health.
Photo: Tor Erik Schrøder / NTB
Denmark will also see a sharp increase in the number of Pfizer vaccines in the coming weeks.
According to Danmarks Radio, the increase is due to the approval of the new Biontech factory in Marburg, Germany by the European Medicines Agency EMA.
Therefore, the doses that the factory has already produced can now be shipped to European countries.
Chief physician Preben Aavitsland is not so concerned about the new factory.
– We are pleased that Biontech-Pfizer has expanded its production capacity. The important thing for us is to get the doses, not which Biontech-Pfizer factories they come from, he says.
Check when you can get vaccinated in the FHI vaccination setting.
Photo: FHI
On par with Denmark
Last Tuesday, FHI published its latest vaccine plan. It says that by mid-July, all adults over the age of 18 should have received their first dose of coronary vaccine.
On April 1 of this year, 12.90% of the Norwegian population had received at least one dose of vaccine.
This is roughly on par with Denmark, according to figures from Our World in Data:
- Finland: 16.8 percent have received the first dose
- Iceland: 14.44 percent have received the first dose
- Denmark: 12.92 percent have received the first dose
- Sweden: 11.56 percent have received the first dose
Israel has the highest proportion of vaccinated people in the world. There, 60.69 percent of the population has received at least one dose.
In Europe, the UK leads the way with 46.13 percent.
These are the coronary vaccines:
AstraZeneca, University of Oxford
The coronary vaccine developed at the University of Oxford prevents COVID-19 symptoms in 70 percent of cases, the company claims. On March 11, vaccination was stopped in Norway and several other countries due to suspicions of serious side effects. On March 25, the company changed the name of the vaccine to Vaxzevria.
The AZD1222 vaccine is based on the monkey ChAdOx1 virus. This virus has been modified so that it cannot make copies of itself, so it does not lead to disease. Researchers have also changed the virus to carry additional information. The additional information causes your body to produce the so-called “spike protein” of the coronavirus.
What happens is the following: You get the vaccine in your body. The vaccine virus enters your cells. Inside the cells, the production system discovers the additional information. Many copies of the “spike protein” are made. These copies are secreted by cells. Your immune system detects these proteins. An immune response is triggered. Antibodies against the coronavirus are produced and the immune system remembers that it is something to react to.
You have been vaccinated.
Biontech, Fosun Pharma and Pfizer
The German pharmaceutical company BioNTech reports that its coronary vaccine has been shown to be 95 percent effective. Norway started vaccination with this on December 27, 2020.
The BNT162b2 vaccine relies on your body’s system for building things. The vaccine is just building instructions for the cells. The instructions are based on the same codes that cells use all the time for this purpose. These are called mRNAs or “messenger ribonucleic acids.”
What happens is the following:
The vaccine is injected into your body. The information from the vaccine reaches the machines in the cells that make proteins. These machines create copies of the so-called “spike protein” of the coronavirus. These proteins are secreted by cells and detected by the immune system. The immune system reacts in the same way as if the real coronavirus had entered the body. Antibodies are produced and the immune system remembers that the coronavirus is something else to react to.
You have been vaccinated.
Johnson and Johnson
The vaccine was approved for use in the EU and Norway on March 11.
Ad26 vaccine. COV2.S is based on the ad26 virus. It is a cold virus that circulates among humans. This virus has been modified by researchers so that it cannot cause disease in humans. It also carries an extra gene, a little extra information. The extra information causes your body to produce the coronavirus’s so-called “spike protein.”
What happens is the following:
You get the vaccine in your body. The vaccine virus enters your cells. Inside the cells, the production system discovers the additional information. Many copies of the “spike protein” are made. These copies are secreted by cells. Your immune system detects these proteins. An immune response is triggered. Antibodies against the coronavirus are produced and the immune system remembers that it is something to react to.
You have been vaccinated.
Novavax with partners
Novavax expects results in early 2021.
The NVX-CoV2373 vaccine is based on what are called nanoparticles. These are microscopic structures. The Novavax vaccine has nanoparticles that are primarily an extract from the Quillaja saponaria plant. This extract is used in much of the world as a food additive, but it also has medicinal properties. In addition, the vaccine particles are made up of cholesterol and fatty acids. The particles also carry the “spike protein” of the coronavirus. These nails are produced in genetically modified yeast cells and are added to the particles in the production process.
What happens is the following:
The vaccine works in two ways. Nanoparticles make your immune system react better and spike proteins make the immune system react as if a real coronavirus has entered the body.
You have been vaccinated.
Modern
Moderna is approved in the EU and Norway. Modern vaccination is ongoing in Norway
The mRNA-1273 vaccine relies on your body’s system to build things. The vaccine is just building instructions for the cells. The instructions are based on the same codes that cells constantly use for this purpose. These are called mRNAs or “messenger ribonucleic acids.”
What happens is the following:
The vaccine is injected into your body. The information from the vaccine reaches the machines in the cells that make proteins. These machines build copies of the so-called “spike protein” of the coronavirus. These proteins are secreted by cells and detected by the immune system. The immune system reacts in the same way as if the real coronavirus had entered the body. Antibodies are produced and the immune system remembers that the coronavirus is something else to react to.
You have been vaccinated.
In this phase, the vaccine is given to a small group of young, healthy people to see if the immune system responds. Researchers are also investigating whether it causes powerful and perhaps dangerous side effects. In addition, based on the results, it is estimated how much vaccine should be administered.
In this phase, the vaccine is given to a larger group that is made up more broadly. The goal is to find variations in the response of the immune system and more data on side effects and the most reasonable amount of vaccine.
In this phase, it is investigated if the vaccine provides protection against the disease and if it causes more rare side effects. Several thousand people receive the vaccine and several thousand people receive a sham vaccine. Nobody knows who gets what. This is to ensure good scientific data.
The vaccine is ready for distribution.
The vaccine is approved for use in the EU and Norway.
